BioSpace News Archive

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, announced the hiring of Jaye Thompson, PhD as Vice President Clinical and Regulatory Affairs to oversee the upcoming GP2 Phase III clinical trial on a full time basis.

The board of directors of Medtronic plc (NYSE: MDT) on Friday, March 5, 2021 , approved the fiscal year 2021 fourth quarter cash dividend of $0.58 per ordinary share, representing a 7.4 percent increase over the prior year. This quarterly declaration is consistent with the dividend announcement made by the company in May 2020.

INNOVO adds significant incremental investment for pioneering home-based treatment for stress urinary incontinence, a condition that impacts 1 in 3 women worldwide Netherland’s Borski Fund backs female-led, femtech focused companies

Therapeutic Research Center, LLC, a portfolio company of Levine Leichtman Capital Partners, announced that it has acquired CE Resources, Inc., d/b/a NetCE.

Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that Craig Fraser , president and chief executive officer, will present at the H.C. Wainwright Global Life Sciences Conference

The group of concerned shareholders Concerned Shareholders of FSD Pharma Inc. which includes two founding directors, Anthony Durkacz and Zeeshan Saeed , are pleased to announce that they were successful in their request that the Ontario Superior Court of Justice order the Company to accelerate the date of its previously called annual shareholders meeting.

ReForm Biologics , a company developing a new generation of bio-innovative biologic medicines to improve patient access, safety and convenience, announced the expansion of its patent portfolio with issuance of its first patent in China, Patent No. CN ZL20158003.

-- Follows recent appointments of Barbara Kosacz and Matthew Fust to ArsenalBio’s Board of Directors and Ken Drazan as Chairman of the Board -- -- Expansion of leadership will support programmable cell therapy pioneer’s continued pipeline, business and operations scale-up --

OpGen today announced the release of a new peer-reviewed publication that demonstrates that the Unyvero Hospitalized Pneumonia (HPN) panel is a reliable and rapid diagnostic test with high negative predictive value for the detection of bacterial pathogens directly from native lower respiratory tract samples, allowing identification of bacterial co-infections in hospitalized patients with COVID-19 pneumonia in just five hours.

Minerva today reported key business updates and financial results for the fourth quarter and fiscal year ended December 31, 2020.